Skip to main content
Venus Remedies Ltd. logo

Venus Remedies Ltd. — Investor Relations & Filings

Ticker · VENUSREM ISIN · INE411B01019 LEI · 335800PBHMB6GQMFN127 BSE.NS Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2025-02-10 Regulatory Filings
Country IN India
Listing BSE.NS VENUSREM

About Venus Remedies Ltd.

https://venusremedies.com/

Venus Remedies Ltd. is a research-driven organization specializing in the development and manufacturing of innovative pharmaceutical formulations. The company focuses on critical therapeutic segments, including antimicrobial resistance, oncology, neurology, orthopedics, and pain management. It operates advanced manufacturing facilities and maintains a dedicated research and development wing, the Venus Medicine Research Centre, which prioritizes the creation of novel drug delivery systems and solutions for multi-drug resistant infections. Its product portfolio features a diverse range of injectables and specialized treatments, such as Elores, aimed at addressing complex clinical needs. The company serves a global market, providing healthcare solutions through a commitment to scientific excellence and international regulatory standards.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 100% confidence The document text is extremely short (only 84 characters) and contains only a digital signature with no substantive content or financial data. There is no indication of any report, announcement, or detailed information. According to the rules, such a document is best classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings without specific content.
2025-02-10 English
Copy of Newspaper Publication
Earnings Release Classification · 95% confidence The document contains an announcement dated 06.02.2025 regarding the publication of unaudited financial results for the period ended 31.12.2024. It references Regulation 30 (LODR) which pertains to continuous disclosure obligations for listed companies in India. The document includes financial data tables showing quarterly and nine-month unaudited results, indicating it is a financial results announcement rather than a full annual or interim report. The presence of the phrase 'newspaper publication of unaudited financial results' and the format suggests this is an Earnings Release (ER) type document, which typically announces quarterly or periodical financial results with key highlights. The document is about 15,000 characters, which is consistent with a detailed earnings release. There is no indication that this is a full Annual Report (10-K), Interim Report (IR), or Management Discussion & Analysis (MDA). It is not a regulatory filing or report publication announcement since it contains substantive financial data. Therefore, the best classification is Earnings Release (ER).
2025-02-06 English
Integrated Filing- Financial
Interim / Quarterly Report Classification · 100% confidence The document is titled as an "Integrated Filing (Financial) for the quarter and nine-month period ended December 31, 2024," indicating it covers interim financial results. It references SEBI regulations and includes an Independent Auditor's Limited Review Report on unaudited standalone financial results for the quarter and nine months ended December 31, 2024. The presence of detailed financial statements, including revenue, expenses, profit, and tax details for the quarter and nine months, confirms this is a comprehensive interim financial report. The document is about 15,000 characters long, which is substantial and contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2025-02-05 English
Updates
Regulatory Filings Classification · 100% confidence The document text is extremely short (only 84 characters) and contains only a digital signature with no substantive content or financial data. There is no indication of any report, announcement, or detailed information. Given the lack of content, this document does not fit any specific report category and defaults to the fallback category for miscellaneous filings.
2025-02-04 English
Financial Result Updates
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement from Venus Remedies Limited dated 4th February 2025, addressed to the National Stock Exchange of India and BSE Limited. It reports the outcome of a Board Meeting held on the same date, specifically approving unaudited financial results for the quarter and nine months ended 31 December 2024, along with a Limited Review report by an independent auditor. The document includes the auditor's limited review report, financial results tables, and notes on accounting treatments such as the write-off of a time-barred FCCB liability. The presence of unaudited financial results for a quarter and nine months, along with a limited review report, indicates this is an Interim / Quarterly Report. The document is substantive and contains actual financial data and analysis, not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2025-02-04 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Venus Remedies Limited dated 4th February 2025, reporting the outcome of a Board Meeting held on the same date. It includes approval of unaudited financial results for the quarter and nine months ended 31 December 2024, along with a Limited Review report by an independent auditor. The document contains detailed financial data such as revenue, expenses, profit before tax, exceptional items, tax expenses, and net profit for the period. The presence of detailed financial statements and the auditor's limited review report indicates this is a comprehensive interim financial report rather than a brief earnings release or a simple announcement. The document is about unaudited standalone financial results for a period shorter than a full fiscal year (quarter and nine months), which fits the definition of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K), nor is it merely an announcement of a report (RPA), as it contains substantive financial data and analysis. Therefore, the correct classification is Interim / Quarterly Report (IR).
2025-02-04 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.